Login to Your Account

Inspire Says INS365 NDA Filing Not Far Off; Stock Jumps 53%

By Kim Coghill

Thursday, October 31, 2002
Inspire Pharmaceuticals Inc. said following a productive meeting with the FDA, it has decided to compile existing data from three trials of its dry-eye product, INS365 Ophthalmic, and submit it for regulatory approval. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription